Search

Displaying results 1101 - 1110 of 4262 in total
  1. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    Delandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy developed by Sarepta Therapeutics. … It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).

  2. Drug

    Nicorandil

    go.drugbank.com/drugs/DB09220
    ApprovedInvestigationalWithdrawn

    It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels.

  3. Drug

    Idursulfase

    go.drugbank.com/drugs/DB01271
    ApprovedInvestigational

    Idursulfase is produced by recombinant DNA technology in a human cell line. … The enzyme contains eight asparagine-linked glycosylation sites occupied by complex oligosaccharide structures.

  4. Drug

    Alemtuzumab

    go.drugbank.com/drugs/DB00087
    ApprovedInvestigational

    [L43397] Alemtuzumab was approved by the FDA in 2001.[L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL).

  5. Drug

    Omega-3-carboxylic acids

    go.drugbank.com/drugs/DB09568
    ApprovedWithdrawn

    [A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386] … The rest of the concentration is represented by docosapentaenoic acid and traces of some other components such as alpha-tocopherol, gelatin, glycerol, sorbitol and purified water.

  6. Drug

    Alendronic acid

    go.drugbank.com/drugs/DB00630
    ApprovedInvestigational

    It functions by preventing resorption of bone[FDA Label][A959].

  7. Drug

    Bempedoic acid

    go.drugbank.com/drugs/DB11936
    ApprovedInvestigational

    [L12144,L12147] It was developed by Esperion Therapeutics Inc. and approved by the FDA on February 21, 2020. … Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease.

  8. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    [L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712] … It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.

  9. Drug

    Alteplase

    go.drugbank.com/drugs/DB00009
    ApprovedInvestigational

    [A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).

  10. Drug

    VidPrevtyn Beta

    go.drugbank.com/drugs/DB16427
    Approved

    VidPrevtyn Beta is an adjuvanted, recombinant COVID-19 vaccine developed collaboratively by GlaxoSmithKline (GSK) and Sanofi Pasteur. … [L49691] It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from